Nes-Ziona, Israel ’ May 29, 2024’ ’ Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company specializing in macrophage reprogramming, has recently closed a registered direct offering to a single healthcare-focused institutional investor. The offering comprised 3,571,429 ordinary shares and clinical milestone-linked warrants, specifically Series A warrants and Series B warrants to purchase up to 3,571,429 ordinary shares each. These shares were offered at a price of $1.40 per share, culminating in gross proceeds of approximately $5.0 million.
This financial injection is significant for Enlivex as it aligns with the company’s ongoing efforts to facilitate advanced clinical trials for Allocetraâ„¢, its novel macrophage-reprogramming immunotherapy. The funds raised will bolster Enlivex’s capacity to expand and accelerate their Phase I/II trials aimed at evaluating the efficacy and safety of Allocetraâ„¢ in patients suffering from moderate to severe knee osteoarthritis.
Enlivex has been making substantial strides in the clinical landscape. On April 16, 2024, the company announced that the Danish Medicines Agency (DKMA) authorized the expansion of their multi-country Phase I/II trial into Denmark, which will include up to 160 patients. This followed the initial regulatory approval from the Israeli Ministry of Health (IMOH) received in January 2024.
The progression into Denmark represents a pivotal step in establishing Allocetraâ„¢ as a transformative treatment for knee osteoarthritis. The trial’s randomized and controlled structure will provide vital data on the therapeutic potential and safety profile of Allocetraâ„¢. By reprogramming macrophages, Allocetraâ„¢ aims to modulate the body’s immune response, presenting a unique approach to managing inflammatory conditions such as osteoarthritis.
We are excited about the progress and support we have received, reflected in the regulatory authorizations and the substantial investment from our recent direct offering, said Dr. Oren Hershkovitz, CEO of Enlivex. These milestones bring us closer to delivering innovative therapies to patients suffering from debilitating conditions like knee osteoarthritis. We remain committed to advancing our clinical programs and bringing Allocetraâ„¢ to market.
The dual developments ’ the successful closing of the direct offering and the regulatory green light from Denmark ’ signify an optimistic future for Enlivex’s clinical ambitions and cement its standing in the biopharmaceutical sector. The company’s endeavors underscore a dedicated commitment to harnessing immunotherapy for the treatment of complex and common inflammatory diseases.
As Enlivex continues its research and clinical trials, stakeholders eagerly anticipate further milestones that will shape the future of osteoarthritis treatment and potentially other inflammatory conditions.
Comments